206650 — EuBiologics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for EuBiologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	39,385	55,467	69,366	96,035	149,195
Cost of Revenue
Gross Profit	15,261	23,613	34,019	55,953	86,197
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	47,323	60,080	83,573	70,281	91,820
Operating Profit	-7,938	-4,614	-14,207	25,754	57,375
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-30,820	-3,338	-14,615	18,457	53,808
Provision for Income Taxes
Net Income After Taxes	-28,025	-3,437	-15,360	18,992	41,264
Minority Interest
Net Income Before Extraordinary Items
Net Income	-27,574	-1,099	-13,879	19,117	41,264
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-27,574	-1,099	-13,879	19,117	41,264
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-765	-18.5	-19.8	672	1,193
Dividends per Share